RecruitingNot ApplicableNCT06155188

Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia

A Novel Post-transplant Regimen of PT/FLU+CY for Selectively Promoting Unrelated Cord Blood Engraftment in Haploidentical-cord Transplantation in Childhood Leukemia: a Single-arm, Multi-center Trial


Sponsor

Nanfang Hospital, Southern Medical University

Enrollment

60 participants

Start Date

Sep 29, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

To determine if the novel regimen of PT/FLU+CY promotes cord blood engraftment in children's leukemia HSCT cohort


Eligibility

Min Age: 1 MonthMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a stem cell transplant approach that combines cells from an unrelated cord blood donor with cells from a family member (haplo-cord transplant) in children with leukemia. Researchers are studying whether adding certain chemotherapy drugs after the transplant helps the cord blood cells grow and take hold in the body. **You may be eligible if...** - You are a child diagnosed with acute leukemia - Your doctor has recommended a stem cell transplant **You may NOT be eligible if...** - You have multiple organ dysfunction syndrome (MODS), a serious condition where multiple organs are failing Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREapplying of FLU+CY post-HSCT

The conditioning regimen (PT-Cy/Flu group) consisted of fludarabine (40mg/m2, d-5 to d-3 and d+3, d+4), busulfan (100mg/m2, d-6 to d-3), haplo-PBSC (d0), PTCy (50mg/kg, d+3, d+4) and UCB (d+6).


Locations(1)

Nanfang Hospital

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06155188


Related Trials